NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/22/2025
Back to search
Official data from USPTO
IMMUNOMODULATORY ALPHA NEUTROPHIL (IMAN)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
IMMUNOMODULATORY ALPHA NEUTROPHIL (IMAN)
ST13
US500000098095871Class
1, 5, 42
Filing
98095871
Registration
7765108
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
04/23/2025
Trademark type
Word
Nice classes
1, 5, 42
Filing date
07/21/2023
Registration date
04/22/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/22/2025
Last transaction
04/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
03
Owner location
London
Examiner
LE, KHANH
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
LIfT BioSciences Limited
Representatives
Steven E. Lauridsen TUCKER ELLIS LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in biotechnological manufacturing processes; Chemicals for use in biotechnological product development; Chemical substances for use in the biotechnological industry; media for cell culture for research use in the biotechnological industry; Chemical reagents for use in biotechnologyother than for medical or veterinary use; all of the aforesaid being for use in cell therapyliving cell therapy and the treatment of cancer
Class 5
Biotechnological immune cell preparations for medical use; all of the aforesaid being for use in cell therapyliving cell therapy and the treatment of cancer
Class 42
Biotechnological research; Biotechnology research; Research relating to biotechnology; Biotechnological research relating to industry; Research and development in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Information on the subject of scientific research in the field of biochemistry and biotechnology; all of the aforesaid relating to cell therapyliving cell therapy and the treatment of cancer
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/22/2025
PUBO
PUBLISHED FOR OPPOSITION
03/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/06/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/05/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/03/2025
GNFR
FINAL REFUSAL E-MAILED
02/03/2025
CNFR
FINAL REFUSAL WRITTEN
02/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/23/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/23/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/23/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
10/30/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
10/30/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/31/2024
GNRT
NON-FINAL ACTION E-MAILED
07/31/2024
CNRT
NON-FINAL ACTION WRITTEN
07/31/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/01/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/29/2024
GNRT
NON-FINAL ACTION E-MAILED
03/29/2024
CNRT
NON-FINAL ACTION WRITTEN
03/29/2024
DOCK
ASSIGNED TO EXAMINER
03/26/2024
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
01/28/2024
ALIE
ASSIGNED TO LIE
01/25/2024
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/21/2023
NWAP
NEW APPLICATION ENTERED
07/25/2023
Continuous trademark protection
Get notified about every new filing that threatens IMMUNOMODULATORY ALPHA NEUTROPHIL (IMAN) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.